Associated Papers
Harnessing genomic profiling for improved urothelial cancer outcomes.
Yu EM et al.
Expert Review of Anticancer Therapy, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
41361008 (PubMed )
Supplement: 41588_2025_2431_MOESM3_ESM.xlsx › S7_Reported_resistance
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers.
Hoskins EL et al.
Npj Precision Oncology, 2025
40610725 (PubMed )
Supplement: 41698_2025_889_MOESM5_ESM.xlsx › Sheet1
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Necchi A et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2024
Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y et al.
Journal for Immunotherapy of Cancer, 2023
37777251 (PubMed )
Supplement: jitc-2022-006643supp001.pdf
Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort.
Zhan Q et al.
Ebiomedicine, 2021
34839264 (PubMed )
Supplement: mmc5.xlsx › Sheet1
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY et al.
Genome Medicine, 2021
34059130 (PubMed )
Supplement: 13073_2021_898_MOESM3_ESM.xlsx › SuppTable1
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
32461694 (PubMed )
Supplement: NIHMS1582596-supplement-1582596_Supp_Tab1-5.xlsx › Table_S2._Composite_mutations
A novel S269C mutation in fibroblast growth factor receptor 3 in a Japanese child with hypochondroplasia.
Takahashi I et al.
Human Genome Variation, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
29312610 (PubMed )
Supplement: oncotarget-08-109319-s003.docx
Achondroplasia: Development, pathogenesis, and therapy.
Ornitz DM et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists, 2017
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.
Chen H et al.
Elife, 2017
Fibroblast growth factor signaling in skeletal development and disease.
Ornitz DM et al.
Genes & Development, 2015
A novel variant of FGFR3 causes proportionate short stature.
Kant SG et al.
European Journal of Endocrinology, 2015
Select a paper to view details